Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut
Open accessThe DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Abstract
The pathogenesis of inflammatory bowel disease (IBD) is multifactorial with data suggesting the role of a disturbed interaction between the gut and the intestinal microbiota. A defective mucosal barrier may result in increased intestinal permeability which promotes the exposition to luminal content and triggers an immunological response that promotes intestinal inflammation. IBD patients display several defects in the many specialized components of mucosal barrier, from the mucus layer composition to the adhesion molecules that regulate paracellular permeability. These alterations may represent a primary dysfunction in Crohn's disease, but they may also perpetuate chronic mucosal inflammation in ulcerative colitis. In clinical practice, several studies have documented that changes in intestinal permeability can predict IBD course. Functional tests, such as the sugar absorption tests or the novel imaging technique using confocal laser endomicroscopy, allow an in vivo assessment of gut barrier integrity. Antitumor necrosis factor-α (TNF-α) therapy reduces mucosal inflammation and restores intestinal permeability in IBD patients. Butyrate, zinc, and some probiotics also ameliorate mucosal barrier dysfunction but their use is still limited and further studies are needed before considering permeability manipulation as a therapeutic target in IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Confocal laser endomicroscopy images from a healthy subject (a) and an Ulcerative Colitis (UC) patient with inactive disease (b). UC patients display increased crypt diameter, intercryptic distance, and perivascular fluorescence. Courtesy of Dr. A. Buda and with permission of Journal of Crohn's and Colitis [105]; © inclusion under a Creative Commons license or any other open-access license allowing onward reuse is prohibited.](https://figures.cochat.ai/paper-figures/2164d4b5b56e4db78a431b3045efb19f/intestinal-permeability-in-inflammatory-bowel-disease-pathogenesis-clinical-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This condition, known as intestinal permeability or leaky gut, has been implicated in the pathophysiology of various GI, as well as extraintestinal disorders [120,121,122], including PD [117,123,124,125,126,127,128]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 5×
“As a matter of fact several defects in bacterial recognition and processing have been documented in CD patients carrying particular genetic polymorphisms, chiefly of pattern-recognition receptors such as NOD2/CARD15 [68, 69] and genes involved in autophagy like ATG16L1 and IRGM [70–72].”
BackgroundInfluentialA frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173 · cited 1×
“[9] “permeability” is defined as a functional feature of this barrier that on one hand allows the coexistence with bacterial symbionts necessary for our organism and on the other hand prevents luminal penetration of macromolecules and pathogens [10, 11].”
BackgroundReview article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721
Genetics and pathogenesis of inflammatory bowel disease
Khor, B., Gardet, A., & Xavier, R. J. (2011) · Nature · doi:10.1038/nature10209 · Cited by 2,614
MICROBIAL ECOLOGY OF THE GASTROINTESTINAL TRACT
Savage, D. C. (1977) · Annual Review of Microbiology · doi:10.1146/annurev.mi.31.100177.000543 · Cited by 2,436 · cited 1×
“It is estimated that the total bacterial cell count in our body exceeds ten times the total number of human cells, with more than one thousand species hosted in the gastrointestinal tract [1, 2].”
BackgroundMachiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · cited 1×
“Another potential mechanism of action is the restoration of butyrate-producing bacteria: UC patients have reduced bacterial species like Faecalibacterium prausnitzii [133, 139] and supplementation with butyrate-producing species or probiotics along with preformed butyrate showed efficacy in experimental models [140, 1…”
BackgroundHampe, J., Franke, A., Rosenstiel, P., Till, A., Teuber, M., Huse, K., Albrecht, M., Mayr, G., De La Vega, F. M., Briggs, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1954 · Cited by 1,897
Intestinal barrier function: molecular regulation and disease pathogenesis
Groschwitz, K. R., & Hogan, S. P. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.038 · Cited by 1,775 · cited 1×
“The mechanical cohesion of these cells and the regulation of paracellular permeability of ions and smallmolecules are ensured by three types of junctional complexes, namely, tight junctions (TJs), adherence junctions, and desmosomes [24, 26, 27].”
BackgroundIntestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755 · cited 6×
“Both the probes are equally affected by gastrointestinal dilution, motility, bacterial degradation, and renal function; thus, the ratio allows for correcting possible confounding factors [9, 82].”
BackgroundInfluential
Research works printed but not linked: 1
- D'Incà R. Di Leo V. Martines D. Can permeability to sugars predict relapses in Crohn's disease? Gut 1993 34 1, supplement S50 S73
Cited by
Items 401–500 of 759
He, S., Chen, H., Xi, H., Sun, G., Du, B., & Liu, X. (2025) · Mediators of Inflammation · doi:10.1155/mi/8742817 · Cited by 12
“It exerts signi fi cant in fl u-ence on host immunity by modulating in fl ammatory responses through its metabolites and interaction with immune cells.”
Kimono, D. A. (2021) · Military Medical Research · doi:10.1186/s40779-021-00341-4 · Cited by 14
Polymeric Systems for Colon-specific Mesalazine Delivery in the Intestinal Bowel Diseases Management
Tavares, A. G., de Araújo, J. T. C., Duarte, J. L., Silvestre, A. L. P., Filippo, L. D. D., & Chorilli, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220707102912 · Cited by 14
The Association between Infant Colic and the Multi-Omic Composition of Human Milk
Chandran, D., Warren, K., McKeone, D. J., & Hicks, S. D. (2023) · Biomolecules · doi:10.3390/biom13030559 · Cited by 12
Zhang, Y., Anderson, R. C., You, C., Purba, A., Yan, M., Maclean, P. H., Liu, Z., & Ulluwishewa, D. (2024) · Microorganisms · doi:10.3390/microorganisms12050873 · Cited by 12
“…this, a leaky intestinal barrier, characterised by compromised TJs, has been implicated in gastrointestinal disorders (such as inflammatory bowel disease [3], irritable bowel syndrome [4], and celiacs disease [5]), as well as systemic disorders (such as type 1 diabetes and multiple sclerosis) [6].”
BackgroundDisease-related information requirements in patients with Crohn’s disease
Wu, Q., & Zhong, J. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s169706 · Cited by 12
“It may be related to genetic factors, microbial infection, and abnormal autoimmunity.(1,2) To date, the disease is responsible for enormous social and financial burdens for patients and society, and has evolved to become one of the major health concerns in People’s Republic of China.”
BackgroundHosic, S., Lake, W., Stas, E., Koppes, R. A., Breault, D. T., Murthy, S. K., & Koppes, A. N. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00633-0 · Cited by 13
Intestinal Microbiome, Akkermansia muciniphila, and Medical Nutrition Therapy.
Bland, J. K. S. (2016) · PubMed · Cited by 12
Wang, Y., Qiao, M., Yao, X., Feng, Z., Hu, R., Chen, J., Liu, L., Liu, J., Sun, Y., & Guo, Y. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14677 · Cited by 11
“57,58 In case of intestinal barrier injury, altered expression of TJ proteins further enhances intestinal perme - ability, facilitating the entry of harmful bacteria-derived molecules and endotoxins into the mucosa, thereby triggering an uncontrolled inflammatory cascade.”
BackgroundCalogiuri, A., Bellisario, D., Sciurti, E., Blasi, L., Esposito, V., Casino, F., Siciliano, P. A., & Francioso, L. N. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1458404 · Cited by 12
Zeng, Y., Yin, Y., & Zhou, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313001 · Cited by 11
Immune modulation for the patterns of epithelial cell death in inflammatory bowel disease
Jiang, Y., Chen, J., Du, Y., Fan, M., & Shen, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114462 · Cited by 18
Arinno, A., Sukmak, P., Kulworasreth, P., Sricharunrat, T., Vaddhanaphuti, C. S., & Pongkorpsakol, P. (2025) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2025.100223 · Cited by 11
“The rate of tight junction-dependent intestinal permeability was also increased in healthy first-degree relatives of Crohn ’ s disease patients (Turpin et al., 2020; Michielan et al., 2015; Buhner et al., 2006).”
Microfluidic organotypic device to test intestinal mucosal barrier permeability ex vivo
Cherwin, A. E., Templeton, H., Ehrlich, A., Patlin, B. H., Henry, C. S., & Tobet, S. A. (2023) · Lab on a Chip · doi:10.1039/d3lc00615h · Cited by 13
Metabolic disrupting chemicals in the intestine: the need for biologically relevant models
Erradhouani, C., Bortoli, S., Aït-Aïssa, S., Coumoul, X., & Brion, F. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13878 · Cited by 12
Gut Microbiome and Sex Bias in Autism Spectrum Disorders
El-Ansary, A. K., Bhat, R. S., & Zayed, N. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00197-3 · Cited by 11
Boerner, K., Luissint, A., & Parkos, C. A. (2021) · Journal of Visualized Experiments · doi:10.3791/62093 · Cited by 12
A Gut-Ex-Vivo System to Study Gut Inflammation Associated to Inflammatory Bowel Disease (IBD)
Gagliardi, M., Monzani, R., Clemente, N., Fusaro, L., Saverio, V., Grieco, G., Pańczyszyn, E., Yissachar, N., Boccafoschi, F., & Corazzari, M. (2021) · Biology · doi:10.3390/biology10070605 · Cited by 11
“A defective mucosal barrier, resulting in compromised permeability, is another allmaker of IBD, resulting in the exposition to luminal content and triggers an immunological response, thus mediating inflammation [41].”
BackgroundAzimirad, M., Gol, S. M. A., Javanmard, E., Mirjalali, H., Yadegar, A., Aghdaei, H. A., Shahrokh, S., Balaii, H., Sadeghi, A., & Zali, M. R. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.19644 · Cited by 12
Dou, D., Chen, L., Di, H., Song, Z.-R., Li, S., Bu, X., Dai, Q., Wang, S., Li, J. X., Zhu, X., et al. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13493 · Cited by 12
Chandra, N., Srivastava, A., & Kumar, S. (2019) · World Journal of Pharmacology · doi:10.5497/wjp.v8.i3.26 · Cited by 14
Zhao, H., Hu, X., Guan, S., Cai, J., Li, W., Zhang, D., Yue, F., Zhu, W. J., Marzorati, M., Li, B., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113858 · Cited by 10
Quantification of Polyethylene Glycol 400 Excreted in the Urine by MALDI-TOF Mass Spectrometry
Kuki, Á., Hashimov, M., Nagy, T., Tóth, C., Zsuga, M., & Kéki, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071341 · Cited by 10
Chen, H., Sun, H., Wu, B., Sun, T., Han, L.-Z., Wang, G., Shang, Y.-F., Yang, S., & Zhou, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111760 · Cited by 10
“diabetes mellitus, Parkinson’s disease, Alzheimer’s disease, cardiovascular disorders [3]-[8] .”
Yu, Y., Bian, Y., Shi, J., Gu, Y., Yuan, D., Yu, B., Shi, L., & Dou, D.-H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2092678 · Cited by 10
“Increased intestinal permeability occurs at the early stage of inflammatory bowel diseases and severely impairs the nutritional function of the intestine [37].”
RetractedSnyder, K. B., & Hunter, C. J. (2023) · Seminars in Pediatric Surgery · doi:10.1016/j.sempedsurg.2023.151310 · Cited by 10
Hoshiko, H., Zeinstra, G. G., Lenaerts, K., Oosterink, E., Ariëns, R. M. C., Mes, J. J., & de Wit, N. J. W. (2021) · Healthcare · doi:10.3390/healthcare9111583 · Cited by 10
A new approach for inflammatory bowel disease therapy
Blander, J. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0416-4 · Cited by 10
Li, T., Yu, F., Zhang, T., Wang, X., Sun, Y., Shuai, G., Chen, Y., Xue, Y., Zhang, J., & Zhang, H. (2024) · Food & Function · doi:10.1039/d3fo04556k · Cited by 9
Salvo, C. D., D’Antongiovanni, V., Benvenuti, L., Fornai, M., Valdiserra, G., Natale, G., Ryskalin, L., Lucarini, E., Mannelli, L. D. C., Ghelardini, C., et al. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2367563 · Cited by 9
Shokravi, A., Luo, Y., & Rabkin, S. W. (2025) · Cells · doi:10.3390/cells14141124 · Cited by 9
“Increased intestinal permeability results in translocation of luminal pathogens and agents into systemic circulation, triggering an inflammatory response [60].”
Engineered spermidine-secreting Saccharomyces boulardii ameliorates colitis and colon cancer in mice
Mohaqiq, M., Palou, R., Li, R., Zhang, G., Vaishnav, H. T., Parweez, F., Moyana, T. N., Carragher, D. M., Cameron, D. W., Ramsay, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-16736-5 · Cited by 9
Advances in blood-based biomarkers of gut barrier integrity
Wouda, S. H., Geertsema, S., van Goor, H., Dijkstra, G. D. H., Faber, K. N., & Bourgonje, A. R. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.01.002 · Cited by 11
Kim, S., Chung, K., Jang, S.-Y., Han, H.-S., Heo, S.-W., Lee, J. K., Kim, H. J., Shin, Y., Ahn, H. S., Lee, S. H., et al. (2023) · Food & Function · doi:10.1039/d3fo01243c · Cited by 9
Toriumi, T., Ohmori, H., & Nagasaki, Y. (2023) · Advanced Science · doi:10.1002/advs.202301159 · Cited by 11
Nutritional roles and therapeutic potentials of dietary sphingomyelin in brain diseases
Alashmali, S. M. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-97 · Cited by 10
“(72,73) The fact that dietary SM/Cer can reduce inflammation and perhaps neuroinflamma‐ tion, supports its likelihood to improve BBB and GBB function, thereby, preventing the transfer of neurotoxic molecules to CNS. Simultaneous consumption of other beneficial SL. SM rich foods (milk, dairy…”
BackgroundThe Leaky Gut and Human Diseases: “Can’t Fill the Cup if You Don’t Plug the Holes First”
Compare, D., Sgamato, C., Rocco, A., Coccoli, P., Ambrosio, C., & Nardone, G. (2024) · Digestive Diseases · doi:10.1159/000540379 · Cited by 10
“Based on this evidence, permeability-oriented therapies to manage these uncurable diseases aroused growing interest in recent years [50].”
Xia, Y., Hu, L., Ren, K., Han, X., Sun, Y., & Li, D. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136739 · Cited by 10
Altered Intestinal Permeability and Drug Repositioning in a Post-operative Ileus Guinea Pig Model
Kim, Y. M., Hussain, Z., Lee, Y. J., & Park, H. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21018 · Cited by 9
“For instance, in inflammatory bowel disease, the permeation of luminal noxious materials via the disruption of intestinal TJ proteins such as claudin causes defects in the mucosal immune system and inflammation.(10,11) A previous study reported that intestinal inflammation and TJ proteins are associated with POI.”
BackgroundJendraszak, M., Gałęcka, M., Kotwicka, M., Schwiertz, A., Regdos, A., Pazgrat-Patan, M., & Andrusiewicz, M. (2022) · Biomolecules · doi:10.3390/biom12121781 · Cited by 9
TIPE-2 ameliorates inflammatory bowel disease in mice via inhibiting STAT3 and NF-kB activation
Zhou, S., Yang, Z., Liu, J., & Ran, M. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.02.005 · Cited by 9
Predictors and clinical outcomes of follow‐up loss in patients with inflammatory bowel disease
Woo, D. H., Kim, K. O., Kang, M. K., Lee, S. H., Jang, B. I., & Kim, T. N. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14258 · Cited by 9
Szandruk-Bender, M., Wiatrak, B., Merwid‐Ląd, A., Dzimira, S., Szeląg, A., Magdalan, J., Szczukowski, Ł., Świątek, P., Duda-Madej, A., Gębarowski, T., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s527041 · Cited by 8
“19 With the above in mind, targeting molecules associated with intestinal barrier disruption holds promise for the treatment and prevention of IBD.”
Ghosh, S., Vanwinkle, Z. M., Bodduluri, S. R., Juin, S. K., Kadari, M., Singh, A., Dryden, G. W., Lawrenz, M. B., Kanneganti, T., Rai, S. N., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73760-3 · Cited by 8
Gut microbiome alterations in hereditary angioedema
Cao, Y., Kan, H., Wang, X. L., & Zhi, Y. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.01.021 · Cited by 8
Lactobacillus plantarum ZJUIDS04 alleviates DSS-induced colitis via modulating gut microbiota
Yu, C., Liu, J., Liu, Z., Ding, Q., Zhu, Q., Chen, N., Fu, J., Valencak, T. G., & Ren, D. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105794 · Cited by 10
Understanding the potential causes of gastrointestinal dysfunctions in multiple system atrophy
Craig, C. F., Finkelstein, D. I., McQuade, R. M., & Diwakarla, S. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106296 · Cited by 8
“Intestinal immune dysregulation is observed in several disorders of the GI tract such as inflammatory bowel disease (Michielan and D'Inca, 2015), celiac disease (Cardoso-Silva et al.”
Sipeki, N., Kovats, P. J., Deutschmann, C., Schierack, P., Roggenbuck, D., & Papp, M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i42.5728 · Cited by 9
“However, whether this phenomenon in IBD is a primary defect or consequence is still under debate[14,16].”
Comorbidity of inflammatory bowel diseases and periodontal pathology
Трухан, Д. И., Филиппович, С. А., & Trukhan, L. Y. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-373 · Cited by 10
Ponzoni, A. A., Speca, S., Hartle, M. D., Gerstenberg, A., Tomezyk, A., Senechal, V., Karnik, S., Dubuquoy, L., Launay, D., Deprez-Poulain, R. F., et al. (2024) · Metabolomics · doi:10.1007/s11306-024-02200-4 · Cited by 8
“Although the aetiology of IBD has not been fully elucidated yet, the integrity of the gut barrier plays a crucial role in disease onset and progression (Michielan & D’Incà, 2015).”
Pharmacology of Intestinal Inflammation and Repair
Deraison, C., & Vergnolle, N. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-084536 · Cited by 10
Measurement of Gut Permeability Using Fluorescent Tracer agent Technology
Dorshow, R. B., Hall-Moore, C. M., Shaikh, N., Talcott, M., Faubion, W. A., Rogers, T. E., Shieh, J. J., Debreczeny, M. P., Johnson, J. R., Dyer, R. B., et al. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)31640-2 · Cited by 8
Chen, W., Liang, R., Yi, Y.-C., Chen, X., Fan, H., Zhu, J.-S., & Zhang, J. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153881 · Cited by 8
Miao, L., Cheong, M. S., Zhang, H., Khan, H. Z., Tao, H., Wang, Y., & Cheang, W. S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474989 · Cited by 11
Go, E.-J., Ryu, B. R., Gim, G.-J., Shin, Y. R., Kang, M. J., Kim, M. J., Baek, J.-S., & Lim, J. D. (2025) · Pharmaceuticals · doi:10.3390/ph18040475 · Cited by 7
“Increased intestinal permeability in IBD can lead to bacterial translocation, exacerbating inflammation [78].”
Chen, C., Guilbaud, L., Marotti, V., Zhang, W., Domingues, I., Yagoubi, H., Vints, K., Xu, Y., & Beloqui, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114411 · Cited by 8
Capeling, M. M., Chen, B., Aliar, K., Penna, E., Lopez, V. I., Foo, C., Rost, S., Holokai, L. L., Tong, X., Phillips, D., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68247-6 · Cited by 7
“We fi rst characterized organoid responses via morphology, degree of cell death, and barrier function, as IBD lesions display increased expression of apoptotic markers and decreased expression of tight junction proteins leading to increased permeability 30 – 32 .”
Sundell, K. S., Berge, G. M., Ruyter, B., & Sundh, H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.883621 · Cited by 7
Judkins, T. C., Solch-Ottaiano, R. J., Ceretto‐Clark, B., Nieves, C., Colee, J., Wang, Y., Tompkins, T. A., Calero, S. E. C., & Langkamp‐Henken, B. (2024) · BMC Gastroenterology · doi:10.1186/s12876-023-03102-w · Cited by 7
“Several chronic immune and metabolic disorders, such as inflammatory bowel disease, type 2 diabetes, and nonalcoholic fatty liver disease have been associated with a disruption of the intestinal barrier resulting in increased intestinal permeability [2–4].”
BackgroundZhang, M., Zhao, J., Ji, H., Tan, Y., Zhou, S., Sun, J., Ding, Y., & Li, X. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03299-2 · Cited by 8
Maarouf, M., Kuczma, M., & Denning, T. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604332 · Cited by 7
“Disruption of the mucosal barrier increases intestinal permeability (6, 7), resulting in immune dysregulation with leukocyte in fi ltration.”
Schisano, C., Narciso, V., Maisto, M., Annunziata, G., Grieco, P., Sommella, E., Tenore, G. C., & Novellino, E. (2019) · European Food Research and Technology · doi:10.1007/s00217-019-03338-5 · Cited by 7
The Atg16l1 gene: characterization of wild type, knock-in, and knock-out phenotypes in rats
Chesney, K. L., Men, H., Hankins, M. A., & Bryda, E. C. (2021) · Physiological Genomics · doi:10.1152/physiolgenomics.00114.2020 · Cited by 8
“One of the most common theories on the initiation of IBD and CD is that damage to the epithelial lining of the gastrointestinal tract causes breaks in the luminal barrier and increases GI permeability thereby increasing the capacity for unwanted luminal bacteria to enter the gut tissues and cause inflammation (30).”
BackgroundManipulation of the intestinal microbiome-a slow journey to primetime
Kriger-Sharabi, O., Malnick, S. D. H., & Fisher, D. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i21.4975 · Cited by 7
Vaccination therapy for inflammatory bowel disease
Liu, Y., & Liao, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2259418 · Cited by 7
“29 Chong He et al. found that induction of TNF-α can promote intestinal mucosal inflammation in IBD patients.”
BackgroundKhemiri, M., Doghri, R., Mrad, K., Friedrich, K., & Oueslati, R. (2019) · Europe PMC (PubMed Central) · Cited by 7
Akkol, E. K., İlhan, M., Karpuz, B., Taştan, H., Sobarzo‐Sánchez, E., & Khan, H. Z. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111589 · Cited by 7
Lijie, S., Shi, L., Leilei, L., Xiuxian, F., Wang, J., Qiang, Y., Shiwei, C., Jing, G., Fenglin, Z., & He, S.-F. (2017) · 中医杂志:英文版 · doi:10.1016/s0254-6272(17)30151-6 · Cited by 7
Psychoneuroimmunological approach to gastrointestinal related pain
Toljan, K., & Vrooman, B. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.10.010 · Cited by 7
“affecting the epithelium (as in UC or CD) [67], the overgrowth of pathogenic bacteria from microbiota [68,69], viruses [68], autoimmune diseases such Coeliac disease [70], and novel causes that could be linked directly to gluten regardless of the autoimmune response [71,72].”
BackgroundA20 Restores Impaired Intestinal Permeability and Inhibits Th2 Response in Mice with Colitis
Chen, D., Ma, L., Hu, T., Liu, J., Chen, B., Yang, P., & Liu, Z. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05860-8 · Cited by 7
Inulin protects against the harmful effects of dietary emulsifiers on mice gut microbiome
Bekar, C., Özmen, Ö., Özkul, C., & Ayaz, A. (2024) · PeerJ · doi:10.7717/peerj.17110 · Cited by 7
“The disrupted mucosal barrier promotes intestinal inflammation by increasing intestinal permeability and exposure to luminal contents, and initiating an immunological response ( Michielan & D’Incà, 2015 ).”
BackgroundRuiz‐Malagón, A. J., Herraiz-Vilela, M., Serrano-Pino, R., García-Ávila, P., Díaz-Suárez, L., Carmona-Segovia, A. D. M., Becerra‐Muñoz, V. M., Jiménez-Navarro, M., Arranz‐Salas, I., López-Villodres, J. A., et al. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i41.110955 · Cited by 8
Gut microbiota: origin or panacea for all ills? Gut microbiota and systemic diseases
Colica, C., Vecchio, I., Aiello, E., Abenavoli, L., Scarlata, G. G. M., & Aiello, V. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108299 · Cited by 9
Lima, M. S. R., Gonçalves, C., Neto, M. D., Macedo, M. H., de Queiroz, J. L. C., da Silva, V. C., Costa, I. D. S., Camillo, C. D. S., Santos, P. P. D. A., Lima, A. Â. M., et al. (2022) · Nutrients · doi:10.3390/nu14214669 · Cited by 6
“However, these drugs can have serious side effects, such as infections and autoimmune complications, as well as long-term reduction of therapeutic effect (Refs [15,16], demanding research on new therapeutic options.”
BackgroundNutraceuticals and biotics in pediatric gastrointestinal disorders
Corsello, A., Scatigno, L., Fiore, G., Baresi, S., Eletti, F., Zuccotti, G., Strisciuglio, C., Dilillo, D., & Verduci, E. (2023) · European Journal of Clinical Nutrition · doi:10.1038/s41430-023-01362-z · Cited by 8
Ye, G., Zhang, J., Peng, J., Zhou, Z., Wang, W., & Yao, S. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16550 · Cited by 6
“5,6 Therefore, the identi fi cation of key molecular targets and regulatory mechanisms affecting the intestinal mucosal barrier injury of UC can provide a new theoretical basis for UC treatment.”
Jiao, X., Li, Y., Hu, Y., Yan, R., Fu, T., Liu, J., & Li, Z. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.01.010 · Cited by 6
Changlin, Z., Ying, Z., Shuhua, Z., Zeng, J., & Chi, H. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/4775606 · Cited by 6
Gibo, N., Hamaguchi, T., Miki, Y., Yamamura, T., Nakaguro, M., Ito, M., Nakamuara, M., Kawashima, H., Hirayama, M., Hirooka, Y., et al. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4313 · Cited by 6
Therapeutic dietary approach to children with autistic spectrum disorder
Torres, F. C. I., Medina, A. C. D. G., Toribio, S. L. G., Guevara, K. K. J., Risco, K. B. L., & Huamán-Saavedra, J. J. (2022) · Revista de la Facultad de Medicina Humana · doi:10.25176/rfmh.v22i4.4729 · Cited by 7
Rella, S., Onyiah, J. C., Baker, C., Singh, V., Her, A., & Rasouli, N. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231207348 · Cited by 6
“48 51 The data backing the association between chronic inflammation and intestinal permeability in patients with T2D is limited, but some human studies suggest increased intestinal permeability is present in T2D.”
BackgroundThisayakorn, P., Thipakorn, Y., Tantavisut, S., Sirivichayakul, S., Vojdani, A., & Maes, M. H. J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1294689 · Cited by 6
Huyut, Z., & Arıhan, O. (2018) · Eastern Journal Of Medicine · doi:10.5505/ejm.2018.20082 · Cited by 6
“In addition structural disorders and inflammatory diseases also have impact on intestinal absorption (26).”
BackgroundSjövall, D., & Staffas, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.05.003 · Cited by 7
Seasonal changes in gut microbiota of sea cucumber over natural aestivation cycle
Zhao, Y., Wang, H., Wang, H., Zhang, L., Sun, H., & Zhang, Y. (2024) · Journal of Oceanology and Limnology · doi:10.1007/s00343-023-3077-6 · Cited by 5
“Therefore, the gut mucosal barrier is essential to maintain intestinal immune function (Pelaseyed et al., 2014; Michielan and D’Incà, 2015).”
Lama, S., Pagano, E., Borrelli, F., Maisto, M., Tenore, G. C., Nanì, M. F., Chacon-Millan, P., Novellino, E., & Stiuso, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063210 · Cited by 5
“…intestinal permeability, as well as increased the β -catenin localization at the colon membrane, maintaining cell–cell adhesion and preventing barrier disruption. β -catenin is a key regulator of intestinal epithelial renewal and the main nuclear effector of canonical Wnt signaling [13,24,25].”
BackgroundKim, K. S., Lee, H., Oh, Y. S., & Jang, S. (2024) · Microbiology Research · doi:10.3390/microbiolres15020047 · Cited by 5
“A leaky gut has considerable influence on the aggravation of IBD, but there is still debate as to whether it is a cause or a result of IBD [5,38].”
BackgroundDeficiency of intestinal alkaline phosphatase affects behavior and microglia activity in mice
Dai, J., Yang, J., Han, S., Li, N., Wang, S., Xia, S., Kim, H.-H., Jun, Y., Lee, S., Kitagawa, Y., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.02.006 · Cited by 5
Langeraert, J., Gasthuys, E., & Vermeulen, A. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107095 · Cited by 5
Gut microbiota orchestrates bone homeostasis: a multi-pathway network from intestine to skeleton
Gong, Y., Ma, X., Wang, L., Zhang, P., Liu, T., Li, Y. D., & Dong, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1767726 · Cited by 5
Buczyńska, A., Grzybowska‐Chlebowczyk, U., & Pawlicki, K. (2023) · Nutrients · doi:10.3390/nu15081804 · Cited by 5
Tu, K.-C., Yu, R.-Y., Lin, Y., Chien, C.-C., & Lu, C. (2023) · European journal of medical research · doi:10.1186/s40001-023-01324-y · Cited by 5
“Impaired mucosal barrier and increased paracellular permeability may enable penetration by bacteria and increase the risks of intestinal infections [32, 33].”
BackgroundLucarini, E., Benvenuti, L., Salvo, C. D., D’Antongiovanni, V., Pellegrini, C., Valdiserra, G., Ciampi, C., Antonioli, L., Lambiase, C., Cancelli, L., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466824 · Cited by 7
İnci, F., Resendez, A., Karaaslan, M. G., Pandrala, M., Mataji‐Kojouri, A., Ahmed, R., Ogut, M. G., Singaram, B., Malhotra, S. V., & Demirci, U. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.117040 · Cited by 5
Hildebrand, F., Cukaci, C., Schoeny, H., Baumgartinger, C., Stelzer, B., Spedicato, M., Frey, T., Catani, M., Schmetterer, K. G., Frey, R., et al. (2025) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-025-05790-7 · Cited by 5
“Intestinal permeability has been described for various conditions such as inflammatory bowel disease [26], Crohn’s disease [27], and irritable bowel syndrome [28].”
Ali, S. N., Liu, C., Yin, Y., Baylink, D. J., & Tang, X. (2024) · Cells · doi:10.3390/cells13171465 · Cited by 5
Ulugöl, S., Hering, L., Manzini, R., Montalban‐Arques, A., Gottier, C., Lang, S., Scharl, M. M., & Spalinger, M. R. (2019) · Inflammatory Intestinal Diseases · doi:10.1159/000499157 · Cited by 5
Jang, J., Hwang, S., Oh, A., Park, S., Yaseen, U., Kim, J. G., Park, S., Jung, Y., & Cha, J.-Y. (2023) · Inflammation Research · doi:10.1007/s00011-023-01707-1 · Cited by 5
“Intestinal barrier dysfunction is often associated with gut inflammation, as observed in inflammatory bowel disease [47, 48], but it is not fully understood whether incompletely absorbed fructose can cause intestinal inflammation.”
BackgroundAbdel-Mohsen, A. F., Salama, N. M., Rashed, L. A., Farag, E. A., & Hameed, A. A. (2018) · The Egyptian Journal of Histology · doi:10.21608/ejh.2018.29264 · Cited by 5
Antoine, T., Béduneau, A., Chrétien, C., Cornu, R., Bonnefoy, F., Moulari, B., Perruche, S., & Pellequer, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125062 · Cited by 4
Metadata
- Authors
- Michielan, A., & D’Incà, R.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Michielan, Andrea
- ORCID
- Michielan, Andrea
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 2015
- Issue
- 1
- Pages
- 628157-628157
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4637104
- OpenAlex
- W2176502392
- Cited by
- 709
- References
- 146
- Citations by year
- 2026: 61 · 2025: 54 · 2024: 86 · 2023: 91 · 2022: 99 · 2021: 82 · 2020: 81 · 2019: 58 · 2018: 38 · 2017: 37 · 2016: 21
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Oxford
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- intestinal permeability, leaky gut, inflammatory bowel disease, Crohn's disease, ulcerative colitis, mucosal barrier dysfunction, gut microbiota, mucus layer, paracellular permeability, adhesion molecules, confocal laser endomicroscopy, butyrate, zinc, probiotics, intestinal inflammation
- MeSH terms
- Humans, Intestinal Mucosa, Permeability, Tumor Necrosis Factor-alpha, Zinc, Inflammatory Bowel Diseases, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.